<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81588">
  <stage>Registered</stage>
  <submitdate>12/09/2006</submitdate>
  <approvaldate>13/09/2006</approvaldate>
  <actrnumber>ACTRN12606000403538</actrnumber>
  <trial_identification>
    <studytitle>Investigation of AV411 in neuropathic pain</studytitle>
    <scientifictitle>A prospective, double-blind, randomized, placebo-controlled trial of AV411 to assess its safety tolerability, pharmacokinetics and preliminary efficacy in the treatment of neuropathic pain</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic neuropathy or Complex regional pain syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral AV411 (20, 30, or 40 mg) two or three times daily for 24 days</interventions>
    <comparator>Oral two or three times daily placebo for 24 days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability </outcome>
      <timepoint>At screening and followed-up daily</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetic profile </outcome>
      <timepoint>On Study Days 2, 8, 21, and 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacodynamic profile </outcome>
      <timepoint>On Study Days 2, 8, 21, and 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Brief Pain Inventory </outcome>
      <timepoint>On Study Days 1, 2, 8, 21, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visual Analog Scale</outcome>
      <timepoint>Daily</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impression of Change (patient)</outcome>
      <timepoint>On Study Days 1, 2, 8, 21, and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of analgesic or adjuvant medications for chronic neuropathic pain</outcome>
      <timepoint>Daily</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between plasma concentrations of AV411 and pain intensity</outcome>
      <timepoint> Assessments on Study Days 2, 8, 21, and 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of diabetic neuropathy or complex regional pain syndrome of at least 6 months duration.-VAS score of 4 cm or higher at screening.-No clinical abnormality in laboratory and urine analyses.-Electrocardiogram within normal limits at screening.-Negative pregnancy test on Study Day 1 for female subjects of childbearing potential.-On stable doses of medications, analgesic or others for at least 8 weeks prior to study enrollment.-Willing to use barrier contraceptive during the period of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to AV411 or its components.-Conditions which might affect drug absorption, metabolism or excretion.-Untreated mental illness, current drug addiction or abuse or alcoholism.-Donated blood in the past 90 days or have poor peripheral venous access.-Platelets &lt;100,000 mm3 or a history of thrombocytopenia.-Known or suspected chronic liver disease.-GFR &lt;= 90 mL/min/1.73m2 (Cockcroft-Gualt).-Female subjects who are pregnant or nursing mothers.-Received an investigational drug in the past 90 days.-Unable to swallow large capsules.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomization</concealment>
    <sequence>Fixed stratified system based on previous treatment</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subject and Investigator are blinded</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>15/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avigen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Avigen, Inc.</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Rolan, MBBS, MD, FRACP, FFPM, DCPSA</name>
      <address>Department of Clinical and Experimental Pharmacology
Medical School-5th Level
University of Adelaide
Adelaide SA 5005 </address>
      <phone>61-8-8303-4102</phone>
      <fax>61-8-8224-0685</fax>
      <email>paul.rolan@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Rolan, MBBS, MD, FRACP, FFPM, DCPSA</name>
      <address>Department of Clinical and Experimental Pharmacology
Medical School-5th Level
University of Adelaide
Adelaide SA 5005 </address>
      <phone>61-8-8303-4102</phone>
      <fax>61-8-8224-0685</fax>
      <email>paul.rolan@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>